Research
Hormonal
Fibrates (specifically fenofibrate) are effective adjunctive treatments for lowering triglycerides and reducing cardiovascular events in type 2 diabetic patients with high triglycerides and low HDL.
If your triglycerides remain high despite statins and lifestyle changes, ask your doctor about adding fenofibrate. It specifically targets high triglycerides and has been shown to reduce cardiovascular events in diabetic patients, even if it doesn't lower mortality.
GoodSupportsHIGH confidence
Current evidence supports the use of fenofibrate in type 2 diabetics with high triglyceride levels.
Why this rating
Supported by meta-analyses and specific trials (FIELD, ACCORD) in diabetic subgroups.
Source
Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Jing Pang et al. · World Journal of Diabetes · 2014
DOI 10.4239/wjd.v5.i2.165
narrative_reviewCited 23×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Statin therapy is the first-line treatment for dyslipidemia in type 2 diabetes, significantly reducing cardiovascular events, although it only modestly lowers triglycerides.Strong
- Niacin is no longer recommended for routine use in type 2 diabetes because large clinical trials failed to show significant cardiovascular benefits despite improving lipid parameters.Strong
- Modest weight loss (5%-10%) in type 2 diabetes significantly lowers plasma triglyceride levels (up to 25%) and normalizes postprandial triglyceride concentrations.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →